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Meta Analysis of Human AlzGene
Database: Benefits and Limitations
of Using C. elegans for the Study of
Alzheimer’s Disease and Co-morbid
Conditions
Behrad Vahdati Nia, Christine Kang, Michelle G. Tran, Deborah Lee and Shin Murakami*
Department of Basic Sciences, College of Osteopathic Medicine, Touro University California, Vallejo, CA, USA
Human genome-wide association studies (GWAS) and linkage studies have identified
695 genes associated with Alzheimer’s disease (AD), the vast majority of which are
associated with late-onset AD. Although orthologs of these AD genes have been studied
in several model species, orthologs in the nematode, Caenorhabditis elegans, remain
incompletely identified, with orthologs to only 17 AD-related genes identified in the
C. elegans database, WormBase. Therefore, we performed a comprehensive search for
additional C. elegans orthologs of AD genes using well-established programs, including
OrthoList, which utilizes four ontology prediction programs. We also validated 680 of
the AD genes as a unique gene from the AlzGene database, including 431 genes
(63%) that are predicted to have orthologs in C. elegans. Another 178 human AD
genes (26%) were associated with one or more other neurological diseases, including
amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease, and schizophrenia.
Of these, there were 105 genes (59%) with orthologs in C. elegans. Interestingly, three
AD genes (ACE, TNF, andMTHFR) were associated with all four of the other neurological
diseases. The human AD genes were enriched in three major ontology pathway groups,
including lipoprotein metabolism, hemostasis, and extracellular matrix organizations,
as well as in pathways that are amyloid related (NOTCH signaling) and associated
with neural (neurotransmitter clearance) and immune (advanced glycation end-product
receptor signaling and TRAF6-NF-kappaB) systems. Thus, the results from this study
provide a potentially useful system for assessing comorbidities that may be associated
with late-onset AD and other neurological conditions. The technical advantages and
limitations of the ortholog searches are further discussed.
Keywords: Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), comorbidity, genome-wide association
study (GWAS), meta-analysis, multiple sclerosis (MS), Parkinson’s disease (PD), schizophrenia (SZ)
INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of dementia but is currently without effective
treatment options. Dementia is also caused by other neurological conditions, and increasing
research and autopsy results reveal thatmany elderly patients exhibit dementia caused bymore than
one brain abnormality (Alzheimer’s Association, 2015).We are interested in studying AD treatment
Vahdati Nia et al. Identification of Worm Alzheimer’s Genes
in a more systematic, but personalized approach based on
genomics. AD can be classified into early onset AD (EOAD)
and late onset AD (LOAD). The human genetic makeup is
one of the main susceptibilities for developing AD. Genome-
wide association studies (GWAS) and linkage studies have
identified 695 human genes associated with Alzheimer’s disease
(referred to as AD genes in this manuscript; www.alzgene.
org; Bertram et al., 2007; Olgiati et al., 2011) . AD genes
are recognized as risk factors, but the causality is yet
unknown.
EOAD affects patients before the age of 65 and is caused
by mutations in APP, PSEN1, or PSEN2 (Campion et al.,
1999). However, most cases (greater than 95%) of AD are
LOAD patients who are over the age of 65 (Alzheimer’s
Association, 2015). Although the mechanism through which
LOAD occurs remains unknown, there are certain genes that
have been identified as risk factors, such as the presence of
APOE-e4 increasing the chances of developing LOAD (Saunders
et al., 1993). As such, it can be said that APOE-e4 and other
genetic risk factors for LOAD, compounded with environmental
and lifestyle choices, can influence the development of AD.
Therefore, LOAD can be classified as a progressive multifactorial
disorder.
Exactly how and to what degree the genes contribute to
the development of AD is not well-understood. Direct studying
of the human genes for AD is not an easy task and is very
limited in practice. We reason that studying the genes in
model systems, including the nematodeCaenorhabditis elegans, is
straightforward and ideal for an early stage study. C. elegans, the
first multicellular organism to have its entire genome sequenced,
possesses a genomewith 20,317 protein coding genes (WormBase
Release Letter WS252, 2011)1. From various estimates, roughly
42% of human genes seem to have orthologous counterparts
in C. elegans (Palikaras and Tavernarakis, 2013), and between
humans and C. elegans. The orthologs are from a common
ancestral gene, and thus, are thought to have similar functions.
The wormbase database list well conserved genes, for example
the daf-2 insulin/IGF-1 receptor gene (three human orthologs,
INSR, INSRR, and IGF1R), the age-1 phosphoinositide 3-kinase
catalytic subunit gene (four human orthologs, PI3KA, PI3KB,
PI3KC, and PI3KD).
This study aimed to validate the procedures that identify
orthologs of human AD genes. As a first step, we identified
C. elegans orthologs of human Alzgenes (i.e., genes listed in
the AlzGene.org). Surprisingly, identifying C. elegans orthologs
was not as straightforward as anticipated. It was in part due
to variations among the ortholog gene pools generated by each
search engine used. We utilized two criteria: a shared gene pool
identified by all selected search engines (stringent pool), as well
as a gene pool identified by each search engine (overall pool).
We will use the numbers from the overall pool in this manuscript
unless otherwise noted.
Abbreviations: AD, Alzheimer’s disease; ALS, Amyotrophic lateral sclerosis;
GWAS, Genome-wide association study; MS, Multiple Sclerosis; PD, Parkinson’s
disease; SZ, Schizophrenia disease.
1WormBase Release LetterVer WS227 (2011). 10 August Retrieved 2013-11-19.
WormBase and OrthoList both identified overlapping and
non-overlapping human gene pools. However, we were also
surprised to find that OrthoList, which has consisted of a fixed
number of human genes since 2013, identified more orthologs
than the constantly updated WormBase. Interestingly, we found
that the genes are not only associated with AD, but also presented
as risk factor genes for other neurological diseases including
Amyotrophic lateral sclerosis (ALS), Multiple sclerosis (MS),
Parkinson’s disease (PD), and Schizophrenia disease (SZ); three
AD genes (ACE, TNF, and MTHFR) are associated with all
four diseases, while 178 AD genes are associated with one or
more of the diseases. This study provides cautions about the
functional analysis in this model system as well as an importance
of C. elegans gene counterparts that provides an insight into the
mechanism underlying co-occurring human diseases, which may
in part explain the complexity of AD diseases.
MATERIALS AND METHODS
Dataset
Our overall method has been summarized in Figure 1. We used
the AlzGene database (www.alzgene.org; last accessed January
2017) to extract a list of identified human AD genes from GWAS
and previous linkage studies. The AD genes were then used: (1)
to identify C. elegans orthologs, using OrthoList and WormBase;
(2) to correlate with the genes that are listed in four neurological
disease databases (PDgene.org, MSgene.org, SZgene.org, and
ALSgene.org). To avoid technical complications, Ensembl IDs
were used for human genes and locus IDs for C. elegans genes.
In the AlzGene database, each AD gene was linked to a number
of positive or negative test results from each GWAS study, which
were then used to validate the reliability of the data. Research
outcomes listed as trends or inconclusive were not included in
our study. The latest access to each search program below was on
April 2016 unless otherwise noted.
Orthology Identification
WormBase
In order to find the appropriate ortholog counterparts of AD
genes in C. elegans, we performed matching registry tests using
WormBase (www.wormbase.org; accessed on 2016; Stein et al.,
2001). WormBase is a consortium that contains biological and
genomic information on C. elegans and other related nematodes.
The database is regularly updated based on new research
submissions and provides lists of homolog genes between
C. elegans and other species. We experienced difficulty using
the default search menu because it did not consistently provide
the genes we were looking for. For this reason, we performed
multiple searches using gene names, protein names, and locus
IDs to generate a complete list. As an additional measure to avoid
missing any genes, we also used BLASTP (protein-protein Basic
Local Alignment Search Tool) match results from WormBase
to confirm that the procured gene similarity default browser
matched the registry results based on gene data (Wheeler et al.,
2008).
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FIGURE 1 | Illustrates the methodology used in this study. We selected our set of AD genes from AlzGene database and identified orthologs in C. elegans and
genes common to multiple neurological disorders.
OrthoList
In order to validate the completeness of WormBase’s results,
OrthoList was the second database we used to obtain a second
list of orthologous AD gene counterparts in C. elegans. We also
chose OrthoList as a control database because it contains a fixed
number of genes (Aug. 2013) (Shaye and Greenwald, 2011).
OrthoList is a database compiled from the meta-analysis of four
unique programs which predict orthologous genes (Shaye and
Greenwald, 2011; accessed on 2016). The four programs are:
Ensembl Compara, InParanoid, Homologene, and OrthoMCL
(described separately below). We then compared the matched
registry test results produced from WormBase against those
of OrthoList and identified the AD genes matched by both
programs. The list of genes generated by OrthoList was also
divided based on the number of C. elegans genes associated with
each human AD gene. In cases where more than one C. elegans
genes was associated with a single human gene, they would be
labeled as orthologs with multipleWormBase IDs; if only a single
C. elegans gene was associated with a single human gene, it would
be labeled as an ortholog with a single WormBase ID.
Ensembl Compara
It uses both sequence level and gene level analysis to obtain data
on cross-species, and phylogenetic trees are used to represent
such data. Their Protein trees include a protein associated with
a specific gene based on NCBI BLAST+ e-values to assess the
level of homology. These proteins are then clustered and aligned
using different techniques (ensemblgenomes.org; accessed on
2016; Kersey et al., 2016).
InParanoid
It uses NCBI BLAST to calculate and create orthologous
groups of two complete proteomes (Remm et al., 2001).
Each orthologous group contains two seed orthologs that
are determined by two-way best hits between the proteomes.
Additional sequences are added to each group based on the
closeness of the sequences in the proteomes to the corresponding
seed orthologs (inparanoid51.sbc.su.se/cgi-bin/faq.cgi., 2001).
HomoloGene
It compares the protein and sequence makeup of different species
with either a complete genome or at least 10,000 UniGene entries
to create putative homology groups. BLASTP is used to assess
the homology of the genes and different species are then divided
based on their genomic makeup similarity (www.ncbi.nlm.nih.
gov/homologene., 2007).
OrthoMCL
It uses BLASTP on proteins and computes the percent match of
sequences based on their length (Li et al., 2003). A threshold is set
for the BLAST results and only matches with e-values of less than
1e-5. Based on these results, possible ortholog, inparalog, and co-
ortholog pairs are obtained. Lastly, OrthoMCL is used to cluster
these pairs into groups (http://orthomcl.org/orthomcl/., 2014).
Gene Ontology and Other Neurological
Disease Analyses
Ontology analysis was performed with PantherDB and
UniProtKB, Swiss-Pro (www.ebi.ac.uk/QuickGO; Binns et al.,
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2009). The results of PantherDB were inconclusive due to either
missing or incomplete lists of functions for individual genes.
Thus, we used UniProtKB, Swiss-Pro in this study. The ontology
for each gene was classified into three gene ontology (GO)
sections: GO biological process, GO molecular function, and
GO cellular component. The gene ontologies for the selected
genes were categorized to determine possible common or shared
ontologies.
Reactome analysis (www.reactome.org) is a type of ontology
analysis combined with cluster analysis (Milacic et al., 2012;
Fabregat et al., 2016). We used Cytoscape ver. 3.3.0 (Java
version: 1.8.0_77) to run the Reactome software plugin,
Reactome FIViz app5 (Wu et al., 2014). The version of
the pathway database was Reactome v56 (released on March
26, 2016; last accessed on May 10, 2016). The Reactome
FIViz was used to determine enrichment in the Functional
Interaction (FI) network, the pathway enrichment of the
genes of interest, followed by converting the results to
interactomes. Statistics and false discovery rate (FDR) were
calculated by the Reactome FIViz. Bonferroni correction was
made to control familywise false positives, namely, type I
error. The Reactome uses Ensembl Compara, which is one
of the four ontology programs we used. Since four programs
should provide a better overview of the orthologs, we did
not use the ontology functions in Reactome FIViz. Twenty
three general reactome pathway groups covered: cell cycle,
cell-cell communication, cellular responses to stress, chromatin
organization, circadian clock, developmental biology, DNA
repair, DNA replication, extracellular matrix organization, gene
expression, hemostasis, immune system, mitophagy, metabolism,
metabolism of proteins, muscle contraction, neuronal system,
organelle biogenesis, and maintenance, programmed cell death,
reproduction, signal transduction, transmembrane transport of
small molecules, and vesicle-mediated transport.
The list of AD Genes we compiled from the AlzGene database
was also used to cross-reference the presence of any common
genes with four other neurological diseases: Parkinson’s disease
(PD), multiple sclerosis (MS), schizophrenia disease (SZ), and
amyotrophic lateral sclerosis (ALS). We adopted the following
databases: PDGene (www.pdgene.org), MSGene (www.msgene.
org), SZGene (www.szgene.org), and ALSGene (www.alsgene.
org) to check for AlzGene counterparts in the aforementioned
diseases. The selected genes were then organized based on
their positive test and negative test results from their associated
studies. For the ALSGene database, since the definite negative
and positive results were not included in the database, we used
the p-value from previous studies. If the p-value was <0.05, we
assumed the data was reliable and counted them as a positive
result; studies with p > 0.05 were regarded as negative. It is
important to note that the details regarding different genes were
available for all of the neural disorders of interest, with an
exception for ALS because the ALSGene database was separate
from the main search engine.
RESULTS
In this study, we define homolog, ortholog, and paralog based
on the definition that shows evolutionary relationships among
genes (Fitch, 1970). A homolog, or a homologous gene, is related
to another gene that comes from the same ancestral DNA. It
includes orthologs and paralogs. Orthologs are genes generated
by speciation. They are in different species and their functions
may be retained during evolution. Paralogs are genes generated
by a gene duplication event. They are in the same species.
Orthologs are functionally conserved more likely than paralogs
are (Li et al., 2005; Hulsen et al., 2006).
To identify orthologs, we performed a meta-analysis using
two different databases embedded in WormBase and OrthoList.
A keyword search of “Alzheimer” in the Wormbase database
pulled out only 17 genes listed, the number of which may
be underrepresented (Accessed January 2017). WormBase is
a well-maintained consortium that includes constant updates
and comprehensive information on C. elegans and related
species (www.wormbase.org). OrthoList is a compendium of
four separate orthology predicting programs that determine
orthologous pairs between human and C. elegans genes (Shaye
and Greenwald, 2011). OrthoList was chosen as a control
database because it contains a fixed number of genes (Shaye and
Greenwald, 2011). To further regulate and validate the overall
experiments, we selected the AlzGene database to provide a
set number of the AD genes (updated April 2011), allowing
us to discern any variations among the different worm gene
search programs we used. Due to the genome projects having
been completed in human and C. elegans, we reasoned that the
increases in gene numbers should be minimal.
Comparison of Predicted Orthologs
between Wormbase and Ortholist
We first validated the AlzGene database with 695 human genes
identified by previous meta-analysis (Alzgene.org). We found
that some genes in the AlzGene database were countedmore than
once, and omitting the redundancies resulted in a revised count
of 680 human AD genes (Supplementary Table 1). These genes
were then used to identify orthologs in C. elegans (Figure 2).
A summary of predicted orthologs identified using WormBase
and OrthoList is shown in Table 1 (also see Supplementary Table
2). Firstly, we used WormBase to match human genes between
human and C. elegans as described in the method. We identified
431 out of 680 human AD genes (63%) as predicted orthologs
(Figure 2). The number was relatively close to what was expected
in C. elegans orthologs (42%; Palikaras and Tavernarakis, 2013).
Secondly, to further validate the results from WormBase, we
expanded the search by using an additional search program,
OrthoList (Shaye and Greenwald, 2011), which is a compendium
of C. elegans genes that utilizes four orthology prediction
programs (Ensembl Compara, InParanoid, Homologene, and
OrthoMCL). Surprisingly, the OrthoList search identified more
genes than the more updated WormBase. Of the unique 680 AD
genes, OrthoList predicted 401 ortholog matches in C. elegans
(59%; Figures 2, 3; Table 1), compared to 352 genes identified by
WormBase (see above).
Thirdly, in order to again compare the results fromWormBase
with OrthoList, we associated each gene, using Ensembl ID. From
the list of 352 ortholog matches produced from WormBase and
401 from OrthoList, both databases were in agreement for 322
of the AD genes predicted to have an orthologous match in
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FIGURE 2 | Distribution C. elegans ortholog identification in WormBase and OrthoList. Out of 680 AD genes, 431 were identified to have an orthologous
match in C. elegans. A discrepancy was observed between the two databases: 30 orthologous matches were uniquely identified by WormBase and 79 from OrthoList.
TABLE 1 | Summary of the orthology searches using WormBase and OrthoList.
Database No. of Human AD genes that have
C. elegans orthologs (%*)
No. of C. elegans
orthologs
No. of the human genes with
positive results (%)
WormBase 352 (52) 950 174
OrthoList 401 (59) 964 203
Specific to WormBase specific or to OrthoList 109 (16) 357 61
Common to WormBase and OrthoList (stringent pool**) 322 (47) 1088 158
Total (overall pool***) 431 (63) 1445 219
Of 695 genes, 680 unique Alzgenes were used to identify C. elegans orthologous counterparts. *The percentages out of 680 genes are shown. **Stringent indicates stringent gene
pool that is identified both by WormBase and by OrthoList. ***Total indicates overall pool of the genes that are identified either by WormBase or by OrthoList. See also Supplementary
Table 2.
C. elegans (Figure 1). And of the 322 common AD genes, 199
genes had a single WormBase ID (i.e., one Alzgene to one C.
elegans gene), and 123 genes had multiple WormBase IDs (i.e.,
one Alzgene to multiple C. elegans genes). Our results showed
that there is a relatively high variability (from 8.5 to 20%) between
the two programs. Seventy-nine AD genes out of the total 401
ortholog matches (20%) were uniquely identified by OrthoList;
30 AD genes out of the total 352 ortholog matches (8.5%) were
uniquely identified by WormBase (Table 1). Two hundred forty
nine genes from the AlzGene database’s list of 680 AD genes, did
not have an ortholog in either of the databases. 19 out of the 249
genes did not have a corresponding Ensembl ID; this class was
classified as non-orthologs.
Comparison with Ensembl Compara,
Inparanoid, Homologene, and OrthoMCL
We evaluated 401 orthologous gene match registry results
generated by OrthoList by directly accessing the four orthology
prediction programs used in it (i.e., Ensembl Compara,
InParanoid, Homologene, and OrthoMCL). We then compared
the data obtained from WormBase with the 4 programs. In
order to ensure that genes selected by each search engine
were orthologs, the Ensembl ID associated with the genes had
to be identified by each search engine. Out of the 401 AD
gene orthologs identified by OrthoList, each program separately
contributed a total of 99 AD gene ortholog matches (25%), and
98 AD genes (24%) were identified by all four various programs
used in the OrthoList database (Figures 2, 3; Table 1). Our
observation of variability among four orthology programs was
consistent with a previous study (Shaye and Greenwald, 2011).
AD Genes as Risk Factor for Multiple
Neurological Disorders
We also compared the AD gene list with the databases of four
other neurological disorders, including ALS, MS, PD, and SZ.
One hundred seventy eight AD genes out of 680 (26%) were
found to be associated with one or more of the four neurological
disorders of interest (Table 3; Supplementary Table 3); 105 out
of 178 AD genes (59%), were human genes predicted to have an
orthologous counterpart (Table 2; See Supplementary Table 1).
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FIGURE 3 | (A) Percentages of the distribution percentages of OrthoList’s 401 AD gene match results among its four unique programs (Ensembl Compara,
OrthoMCL, InParanoid, Homologene). (B) Numbers of the distribution of OrthoList’s 401 AD gene match results.
We discovered that 3 out of the 105 AD genes were shared by all
five neurological disorders: ACE,MTHR, and TNF. Furthermore,
two out of the three genes, ACE and MTHFR, were human
genes predicted to have C. elegans counterparts, acn-1 andmthfr-
1. We further studied the GO of the genes shared in the five
disorders (AD, ALS, MS, PD, and SZ), using UniProtKB, Swiss-
Pro. However, we found numerous terms with general functions
(ranging from 10 to 100 ontological terms) for each gene (data
not shown). For the reason, we did not explore the ontological
functions due to the general nature of the functions.
Reactome Analysis of Human AD Genes
We ran a Reactome analysis of the human AD genes. Reactome
is a free and peer-reviewed pathway database that provides
visualization and analysis of pathway knowledge to support
basic research, genome analysis, and systems biology (Version,
Reactome v56; released on March 26, 2016, and last accessed on
April 22, 2016). Reactome database accommodates searches in 20
different species; in humans, it has 2,007 established pathways,
covering 9,238 proteins. In order to concentrate our search most
effectively, we organized the 680 human AD genes with positive
test results from previous studies (positive genes) and ran the
Reactome’s pathway enrichment analysis for those genes only.
Three hundred fifty six AD genes had positive results (positive
genes) and 324 genes did not meet our criteria to be a positive
gene (Figure 4). We then performed ontology analysis combined
with cluster analysis, using Reactome knowledgebase (referred
to as Reactome analysis; see Method). We set a threshold of
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TABLE 2 | Summary of the human AD genes associated with one or more
of four neurological disorders (PD, MS, SZ, and ALS).
Gene No. of the genes (%)
AD genes associated with one or more of four
neurological diseases
178/680** (26)
AD genes above* that have C. elegans ortholog(s) 105/178 (59)
AD genes above* associated with all four diseases 3/178 (2)
*Alzgenes with one or more of four neurological diseases. **680 unique Alzgenes. See
also Supplementary Table 3.




No. of AD genes that
are associated with
the disorder (%)
No. of AD genes that are
associated with the
disorder and have
C. elegans Orthologs (%)
Amyotrophic lateral
sclerosis
17/178 (10) 11/17 (65)
Multiple sclerosis 77/178 (43) 36/77 (47)
Parkinson’s disease 80/178 (45) 45/80 (56)
Schizophrenia disease 87/178 (49) 51/87 (59)
the false discovery rate, FDR < 0.1, which is roughly the same
as the probability being significant (p < 0.01). The results are
summarized in Table 5.
Reactome analysis of the 356 positive AD genes suggested
significant pathway enrichments of the AD genes in 3 general
reactome groups (see Method for the list of all 23 general
groups). They were metabolism, hemostasis, and extracellular
matrix organization (p < 0.0015; FDR < 0.05; Bonferroni
corrected p < 0.03). The control genes pulled out from the
metabolism group were statistically significant, but we should
consider the significance in metabolism to be dependent on the
gene choice of GWAS studies. The control genes in hemostasis
and extracellular matrix organization were not significant. We
then further investigated specific reactome groups.
Our top result for the enriched pathway analysis was
lipoprotein metabolism (FDR = 6.06E-10; Bonferroni corrected
p= 1.78E-11), which was a sub-pathway topic under metabolism
of lipids and lipoproteins, in addition to lipid digestion,
mobilization, and transport (FDR = 1.00E-07; Bonferroni
corrected p = 5.87E-09) in the hierarchy panel. Within
lipoprotein metabolism, the analysis highlighted chylomicron-
mediated lipid transport (FDR= 6.84E-07; Bonferroni corrected
p = 8.03E-08) and HDL-mediated transport (FDR = 3.23E-06;
Bonferroni corrected p = 5.70E-07). Lipoprotein metabolism
involves 30 proteins, and within it, 14 were found to be shared
in our positively tested AD genes (p = 7.73E-13; FDR = 6.06E-
10; Bonferroni corrected p = 1.78E-11). Many of the hit-genes
were found to overlap with a number of different pathways; for
example, A2M was shared in lipoprotein metabolism, platelet
degranulation, hemostasis, and degradation of the extracellular
cellular matrix (Table 5).
We also further identified specific reactome groups within
the general groups, including signal transduction, neural system,
and immune systems (Table 5). In those general groups, specific
groups were masked by other specific groups within. Therefore,
we further investigated specific reactome groups.
Surprisingly, in specific reactome groups, the amyloid-related
group did not come up with the highest statistical significance.
The group with the highest significance was metabolism related
to lipoproteins, fat-soluble vitamins, and co-factors, as well
as biological oxidations and angiotensins (p < 5.9E-03; FDR
< 0.077; Bonferroni corrected p = 1.36E-01). There was no
significance with metabolism related to carbohydrates (p = 0.72;
FDR = 0.72; Bonferroni corrected p = 1.00), nucleotides (p =
0.85; FDR = 0.85; Bonferroni corrected p = 1.00), and amino
acids (p = 0.44; FDR = 0.44; Bonferroni corrected p = 1.00) and
lysin catabolism (p = 0.01; FDR = 0.10; Bonferroni corrected
p = 0.23). The group with the second highest significance was
hemostasis including platelet regulation (activation, signaling
and aggregation) and fibrin clot, followed by amyloid-related
groups having the third highest significance (NOTCH signaling,
including activated NOTCH1 and signaling by NOTCH 2–4; p<
2.30E-04; FDR < 6.10E-03; Bonferroni corrected p = 5.29E-03).
Other specific groups included but were not limited to amyloid-
related (NOTCH signaling), neural systems (neurotransmitter
clearance), and immune systems (advanced glycation end-
product receptor signaling and TRAF6-NF-kappaB) (Table 5,
Figure 5).
In addition to the NOTCH signaling, the general “Signal
transduction” group demonstrated significance in visual
phototransduction (related to retinoid metabolism and
transport; p < 2.02E-09; FDR < 5.28E-07; Bonferroni corrected
p = 4.65E-08). In contrast, some aging-related “groups” were
not statistically significant, including signaling by insulin (p =
0.96; FDR = 0.96; Bonferroni corrected p = 1.00), regulation
of IGF-1 (p = 0.093; FDR = 0.32; Bonferroni corrected p =
1.00), and post-NMDA activation events (including CREB)
(p = 0.63; FDR = 0.63; Bonferroni corrected p = 1.00). The
Parkinson disease-related group was also not significant (Pink-
Parkin mediated mitophagy) (p = 0.48; FDR = 0.48; Bonferroni
corrected p = 1.00). However, due to the nature of reactomes
being incomplete, it is not clear whether or not negative results
suggest a lack of interaction with AD. Distribution of the control
AD genes among reactome groups was not similar, ruling out the
possibility that the top three reactome groups were selected by
chance.
Genes within our positively tested AD genes for lipid
digestion, mobilization, and transport (Figures 5A, 6A) included
the following sub-processes: arachidonic acid metabolism,
fatty acid metabolism, triacylglycerol metabolism, ketone body
metabolism, cholesterol biosynthesis, regulation of biosynthesis
by SREBP (SREBF), bile acid and bile salt metabolism,
metabolism of steroid hormones, sphingolipid metabolism,
and phospholipid metabolism. Under metabolism of vitamins
and cofactors, hit genes included metabolism of water and
fat-soluble vitamins, as well as cofactors (Figures 5B, 6B). Hit
genes involved in platelet activation, signaling, and aggregation
were involved in GP1b-IX-V activation signaling, effects
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FIGURE 4 | Distribution of the all human AD genes, based on their corresponding number of C. elegans orthologs.
FIGURE 5 | Enriched pathway analysis: The entities in the diagram colored purple are hits within positive gene list. Proteins are rectangles whereas
elongated hexagons are complexes. Different Reactome pathways are highlighted in colors corresponding to their FDR values. (A) Lipid digestion, mobilization, and
transport. (B) Metabolism of vitamins and cofactors. (C) Platelet activation, signaling, and aggregation. (D) Signaling by NOTCH4.
of PIP2 hydrolysis, platelet aggregation (plug formation),
thrombin signaling via proteinase-activated receptors (PARs),
GPVI-mediated activation cascade, and responses to elevated
platelet cytosolic Ca2+ (Figures 5C, 6C). Pathway enrichment
results for NOTCH signaling showed positive AD genes
associated with pre-NOTCH expression and processing, in
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FIGURE 6 | The Reactome pathways displayed in Figure 5 were converted into a functional interaction network using FI network view. Sub-pathways
within the original pathway diagrams were extracted into the FI network as well. Hit genes are displayed in a thick purple border in the FI network view for a hit
pathway. (A) Lipid digestions, mobilization, and transport. (B) Metabolism of vitamins and cofactors. (C) Platelet activation, signaling, and aggregation. (D) Signaling
by NOTCH4.
addition to signaling processes by NOTCH1, 2, 3, and 4. We
elected to show signaling by NOTCH4 in particular because of
its FDR value of 8.240E-5 (Bonferroni corrected p = 2.92E-05)
(Figures 5D, 6D).
DISCUSSION
In this study, we identified 431 human AD genes (overall
pool) and 322 genes (stringent pool) that have C. elegans
counterparts. Given that only 17 genes are listed as Alzheimer’s
disease related genes in Wormbase (accessed January 2017), our
results dramatically increase the number of the genes in the
criterion.
We have performed a meta-analysis of the fixed number
of human AD genes to validate fluctuations among current
programs available. For this reason, we used the AlzGene
database. We used two different programs to identify C. elegans
orthologs: WormBase and OrthoList. WormBase has been
constantly updated, while OrthoList has fixed gene datasets
based on the assumption that there are minimal updates in
the number of genes for C. elegans. However, despite our
prediction that WormBase would provide a comprehensive list
of orthologs, OrthoList contributed more genes thanWormBase.
Moreover, there was a relatively high amount of variability
between WormBase and OrthoList, totaling in 16% (Shaye and
Greenwald, 2011).
In addition, we discovered that a relatively high percentage
of human AD genes had orthologous counterparts in C. elegans
(59%). This percentage is consistent with a previous study: 42%
of human genes have orthologs in C. elegans, and approximately
65% of human genes that cause disease have a counterpart
in C. elegans (Palikaras and Tavernarakis, 2013). Our findings
will also make a major contribution to WormBase’s section
of “Disease Ontology, Alzheimer’s disease,” where there are
currently 10 genes in the section of “Genes used as experimental
models” and 8 genes in the section of “Genes identified as
potential models” (WormBase accessed in April 2016). Our
results from this study will add a new gene set of more than 400
genes.
Each particular search engine from OrthoList picked up a
different number of predicted orthologs between the human and
C. elegans genomes. This was not surprising because each search
engine utilizes different parameters and methods to collect worm
data, followed by a distinct set of criteria to identify predicted
orthologs (described in the Method). Homologene had the least
number of genes identified as orthologs compared to the three
other search engines. Although the reason remains unclear, we
speculate that the lower number may be due to higher specificity
for the values set as a selection parameter for orthologs; the
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procedure is essentially a BLAST search looking at the genome
sequences across different species. Ensembl Compara provided
the most comprehensive orthologous search by creating a list of
322 registry matches out of 401 (Table 4).
More importantly, 178 of the AD genes (26% of total
AD genes) were associated with one or more of four







321 290 119 286
Unique to each
search program
56 21 2 19
different neurological disorders (PD, MS, SZ, and ALS). Thus,
approximately a quarter of the AD genes are associated with
multiple diseases, which may account for some aspects of the
complexity observed in patients with AD and other neurological
disorders. Additionally, 3 AD genes were identified in all four
diseases, of which 2 have orthologs in C. elegans. This raises
the possibility that different neurological diseases may develop
through similar mechanisms and the genes shared between them
can be the common link. A closer study of the three genes:
ACE, MTHR, and TNF functions may reveal the overlapping
pathways that can lead to the development of such diseases.
Tumor necrosis factor (TNF) is associated with insulin resistance
and inflammation, which are characteristics found in Type II
diabetes and can be a contributing factor that can lead to
the pathogenesis of AD (de la Monte and Wands, 2008). A
previous study published in 2011 focused on genes that were well-
associated with LOAD from the AlzGene Database and analyzed
TABLE 5 | Reactome pathway enrichment analysis results.
Pathway No. of total proteins
in pathway
No. of hits in
pathway
p-value FDR value Hit gene
Lipoprotein metabolism 30 14 7.73E-13 6.06E-10 A2M, APOE, ABCG1, LDLR, CETP, HSPG2, APOA4, APOA1, APOA5,




56 15 2.55E-10 1.00E-07 A2M, APOE, ABCG1, LDLR, CETP, HSPG2, APOA4, APOA1, APOA5,
CAV1, APOC2, ABCA1, ALB, LPL, LIPC
Retinoid metabolism
and transport




17 9 3.49E-09 6.84E-07 APOE, LDLR, HSPG2, APOA4, APOA1, APOA5, APOC2, LPL, LIPC
Metabolism of
fat-soluble vitamins




15 8 2.48E-08 3.23E-06 A2M, APOE, ABCG1, CETP, APOA1, APOC2, ABCA1, ALB
Metabolism of vitamins
and cofactors
114 17 8.87E-08 9.94E-06 PTGS2, APOE, LDLR, HSPG2, LRP1, LRP8, LRP2, MTHFD1L, APOA4,
TTR, APOA1, LRAT, APOC2, LPL, MTR, MTHFR, GSTO2
Platelet degranulation 78 14 1.42E-07 1.39E-05 A2M, APP, SERPINE1, CD36, SERPINF2, SERPINA1, TF, IGF1, F13A1,
TGFB1, APOA1, CLU, ALB, HSPA5
Response to elevated
platelet cytosolic Ca2+
83 14 2.97E-07 2.59E-05 A2M, APP, SERPINE1, CD36, SERPINF2, SERPINA1, TF, IGF1, F13A1,




203 21 1.08E-06 8.24E-05 A2M, APP, GAB2, SERPINE1, CD36, SERPINF2, FCER1G, SERPINA1, TF,
DGKB, IGF1, GNA11, F13A1, TGFB1, APOA1, CLU, ALB, CSK, LCK,
HSPA5, PIK3R1
Signaling by NOTCH4 11 6 1.27E-06 8.24E-05 PSENEN, ADAM10, PSEN2, APH1A, APH1B, NCSTN
Signaling by NOTCH3 11 6 1.27E-06 8.24E-05 PSENEN, ADAM10, PSEN2, APH1A, APH1B, NCSTN
Metabolism 1551 77 1.37E-06 8.24E-05 A2M, PTGS2, APOE, SGPL1, RXRA, GSTT1, CD36, DLD, HSD11B1,
MAOA, ABCG1, HMGCS2, ARSB, PPARA, LDLR, PPARG, NOS3, CETP,
MT-ATP8, DHCR24, COX15, AGPAT1, GNB3, ALDH18A1, DPYS, AGT,
MT-CYB, MT-ATP6, NAT2, HSPG2, PCK1, GAPDHS, LRP1, LRP8, LRP2,
DNM2, HMGCR, MTHFD1L, GSTM1, APOA4, TTR, GSTM3, APOA1,
APOA5, NQO1, LRAT, CAV1, APOC2, ABCA1, ALB, CYP19A1, SREBF1,
LPL, FDPS, MTR, ALDH2, HMOX1, ACAD8, MT-ND4, MT-ND6, MT-CO2,
MT-CO3, MT-ND1, GSTP1, MT-ND2, MT-ND3, COMT, MTHFR, ACAN,
GSTO2, GSTO1, GAPDH, PIK3R1, DLST, ALOX5, LIPC, CBS
Hemostasis 454 32 6.50E-06 3.64E-04 A2M, APP, GAB2, SERPINE1, CD36, SERPINF2, FCER1G, PLAT, PLAU,
SERPINA1, NOS3, TP53, TF, DGKB, NOS1, IGF1, LRP8, GNA11, F13A1,
MMP1, TGFB1, APOA1, CAV1, CLU, ALB, CSK, CDK5, LCK, HBG2,
HSPA5, PIK3R1, OLR1
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the shared pathways that included TNF in their list of top 15
genes. TNFalpha is a gene involved in immune function and
implicated in neuroinflammation, which is a downstream effect
of beta-amyloid deposits that leads to the activation of microglia
and potentially results in increasing tissue damage (Wang et al.,
2015).
Although our meta-analytic data for the positive AD genes
demonstrated involvement in a broad range of biological
pathways, concurrent with previous studies, some of our most
significant GO analysis were strongly associated with lipoprotein
metabolism, lipid digestion, mobilization, and transport; these
overlapped in every gene except for one, CAV1 (Table 5). This
adds to the consistent support of cholesterol’s connection and
importance in the pathogenesis of AD given that the brain has
the highest content of cholesterol (∼20%) in ratio to total body
cholesterol (Puglielli et al., 2003).
ACE is involved in the Renin-Angiotensin-Aldosterone
system and implicated in microvascular complications in
Diabetes III (MVCD3) and ischemic strokes. MVCD3 include
pathological conditions that result as a consequence of diabetes
mellitus and include diabetic retinopathy, end-stage renal
disease, and diabetic neuropathy. Low CSF ACE protein levels
have been correlated with increased alpha-beta accumulation in
the brain (Jochemsen et al., 2014).
Previously we have proposed to include feedback from
patients into research when studying health (Murakami
and Halperin, 2014) and provided an example (Murakami,
2016). Similarly, this study was performed in discussion with
Alzheimer’s patients. We incorporated the critique that there
might be a more meaningful approach to AD patients than
simply finding a pool of the AD genes. The discussion prompted
us to explore co-morbidities that might be associated with AD.
We found 178 human genes associated with one or more of
neurological disorders. Identifying common links between the
different neurological diseases may be the key to developing
effective treatments for multiple diseases simultaneously. We
hope to stimulate basic science research with more focus on
patients.
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